Expanding telehealth is a very important way to overcome disparities in healthcare access. Bill to extend telehealth flexibilities clears House committee ama-assn.org/practice-manag… (via AMA)

Today I saw a BC survivor who moved to Boston. She can’t find a PCP for 8 months after calling > 6 places. I ordered mammo, DEXA, labs, colonoscopy for + cologuard. I refilled thyroid meds, BP meds which were out and causing symptoms. This is 🇺🇸

This is happening all over the country. Almost every day, I get a msg from someone whose primary care doctor left practice, or doesn’t have appts for months, & they can’t find someone new. I don’t know what this is, but it’s not a healthcare system. 🇺🇸 #MedTwitter

Dr Sarah Sammons Yep. Every single patient I see in #RhodeIsland. Access to primary care is increasingly an issue ASCO PAC #ASCOAdvocacy and American Cancer Society Cancer Action Network are going to need to take on. Cancer patients who can’t get primary care is a real problem.

From JAMA Surgery: A one-month tailored exercise program, initiated immediately after breast cancer surgery and supplemented with supervised sessions coinciding with surgeon visits, significantly improved shoulder function in patients with breast cancer. ja.ma/3YKOAoI

What’s wild about this is Boston has some of the best medical facilities in the world. Yet there is no access. Same is happening in NYC. My wait time for my new PCP is 6+ mo. And I’m in the medical profession lmao 😥

My Top 10 Breast Cancer Abstracts list at #ESMO24, Where Highly Valuable Studies Will Be Presented👇

Nice and provocative real-world data of ADCs sequencing. Congrats to the authors! 🧐ADC cross-resistance - which may imply TOPO1 resistance as a major resistance mechanism. 🧐Disappointing PFS2 regardless of sequence 🧐No role for intermediate ttx line OncoAlert #bcsm

Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Awesome work LauraRosenbergerMD! A pleasure to work with you always.

Excellent internal discussion by Antonio Giordano, MD PhD about use of CDK4/6 after CDK4/6. Personally I consider if long first line CDK4/6 duration, Palbo treated, no visceral crisis, no RB frameshift mutation or PIK3CA/AKT/pTEN.

Coming soon! Join us on September 10th to discuss how effective communication about palliative care can support families and improve the quality of life for people living with MBC. There will be time to ask questions during this webinar. Register here: mbca.me/3AA4ska

A study that followed ~40K women for 30y beginning in midlife found 3 low-cost, widely avail blood tests—LDL, hsCRP, & Lp(a)—could identify those at high-risk for heart attack or stroke even decades later. All can be modified w/ behavior/meds. #MedTwitter cnn.com/2024/08/31/hea…

I have become a fan of ⁦Peter Attia⁩ since reading his book “Outlive” which discusses the science of longevity and preventative medicine. Here, he breaks down ctDNA for CRC screening. A new blood test doesn’t change the game for CRC screening peterattiamd.com/blood-test-for…

Cardiology has meaningful primary endpoints. “The primary outcome was a composite of total worsening heart failure events (defined as 1st or recurrent hospitalization or urgent visit for HF) and death from cardio causes” What can oncology learn? nejm.org/doi/full/10.10…

Circulating Estrogen Metabolites and Risk of Breast Cancer among Postmenopausal Women in the Nurses' Health Study pubmed.ncbi.nlm.nih.gov/39190182/?utm_…

Excited to welcome Dr. Benjamin Ebert as next CEO of Dana Farber Cancer Institute! Thank you Dr. Laurie Glimcher, the first woman to lead the organization in our long history since October 2016.

what's the new and novel molecule data to look forward in ESMO24 ? My Take 1 - Vimseltinib - oral TKI inhibitor of CSF-1R ( macrophage colony stimulating factor) phase 3 study for rare tenosynovial giant cell tumor 2- Dazostinag ( TAK-676) -STING ( stimulator of

“The number needed to treat (NNT) to prevent one distant recurrence is 37 (100/2.7) for ribociclib, and estimated cost of around $400,000, for 3 years of therapy for one individual patient, and the cost to prevent one distant disease-free recurrence is $14.8 million.”

Does physical activity play an immumomodulatory role in breast cancer? 🏃🏼‍♀️‍➡️🏋🏽‍♀️ In this🇮🇹work by Ornella Garrone et al. out in ESMO Open, physical activity ⬇️ cytokine levels during neoadjuvant CT and was associated with ⬆️ pCR OncoAlert esmoopen.com/article/S2059-…